Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lorcaserin + phentermine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lorcaserin + phentermine is a combination of two pharmaceutical agents used for weight management in adults with obesity or overweight with at least one weight-related comorbidity. Lorcaserin is a selective serotonin 5-HT2C receptor agonist that acts on the hypothalamus to promote satiety and reduce food intake. Phentermine is a sympathomimetic amine that suppresses appetite by increasing norepinephrine release in the central nervous system. The combination has been studied for enhanced short-term weight loss, showing greater efficacy than either agent alone, though both drugs carry risks of adverse effects including neuropsychiatric symptoms and cardiovascular concerns[1][2][5].
- Brand names
- Qsymia
- Other names
- lorcaserin hydrochloridephentermine hydrochloride
02
Targets
SERT (Sodium-dependent serotonin transporter)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)HTR2B (5-Hydroxytryptamine Receptor 2B)
Beyond the preview
Go deeper on lorcaserin + phentermine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lorcaserin + phentermine.